We would like to express our sincere appreciation for your continued support and patronage. We are pleased to announce that, effective July 1, 2025, Mr. Jun Yokomizo has been appointed Representative Director and President of MEGGLE Japan Co., Ltd. We would also like to inform you that the former Managing Director, Mr. Thomas Pilgram, stepped...
We are pleased to announce the relaunch of the official MEGGLE Excipients website：www.meggle-excipients.com The new website features a modern, refined design in MEGGLE’s signature blue and is fully optimized for all devices, including desktops, tablets, and smartphones. Our customer portal has also been enhanced, allowing registered users to access order history for sample requests, easily...
We are pleased to announce the launch of MicroceLac® Plus, the upgraded version of our co-processed excipient MicroceLac® 100.This new product combines 35% lactose monohydrate with 65% microcrystalline cellulose, significantly enhancing tablet compressibility.Designed specifically for direct compression, MicroceLac® Plus enables the production of robust tablets with high hardness and low friability, even with challenging APIs...
In response to the growing awareness of the risks associated with nitrosamines, MEGGLE has launched three new Low-Nitrite Grade Lactose Monohydrate products.(Click here for details)These products are standardized to contain ≤0.10 ppm of nitrite in every batch.With our new Low Nitrite excipients, we offer manufacturers a trusted solution to meet regulatory requirements and improve formulation safety. ＜Product Lineup＞・GranuLac®...
We will be presenting a panel exhibition on nitrosamines at the 40th Annual Meeting of the Academy of Pharmaceutical Science and Technology, Japan,to be held over three days from Thursday, May 22 to Saturday, May 24, 2025, at TFT Hall in Koto-ku, Tokyo. In response to the increasing awareness of nitrosamines in recent years, MEGGLE...
We understand that time is limited, and reviewing a full sustainability report may not always be feasible. That’s why we’ve created a concise whitepaper, highlighting the most crucial aspects of sustainability with a focus on our Business Unit Excipients and the pharmaceutical industry.
Lactose Monohydrate Low Endotoxin is MEGGLE´s protective sieved product, which is not specified in PSD, but in microbiological quality and endotoxins. Due to the characteristics of the product, Lactose LE is suitable for use in inhalation and parenteral applications. Please do not hesitate to contact us for samples.
Compaction Blend M is versatile and suitable for a wide range of technical applications, including: Please do not hesitate to contact us for samples.